Renalytix Plc
RENX.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £729 | £522 | £586 | £535 |
| % Growth | 39.7% | -10.9% | 9.5% | – |
| Cost of Goods Sold | £331 | £422 | £550 | £601 |
| Gross Profit | £398 | £100 | £36 | -£66 |
| % Margin | 54.6% | 19.2% | 6.1% | -12.3% |
| R&D Expenses | £0 | £921 | £1,062 | £2,216 |
| G&A Expenses | -£718 | £3,271 | £4,499 | £7,095 |
| SG&A Expenses | -£718 | £3,271 | £4,499 | £3,854 |
| Sales & Mktg Exp. | £0 | £0 | £0 | -£3,241 |
| Other Operating Expenses | £4,551 | £1 | £0 | £417 |
| Operating Expenses | £3,833 | £4,193 | £5,561 | £6,487 |
| Operating Income | -£3,435 | -£4,093 | -£5,525 | -£6,136 |
| % Margin | -471.2% | -784.1% | -942.8% | -1,146.9% |
| Other Income/Exp. Net | -£449 | -£633 | -£1,549 | -£1,607 |
| Pre-Tax Income | -£3,884 | -£4,726 | -£7,074 | -£7,743 |
| Tax Expense | -£2 | £2 | £0 | £0 |
| Net Income | -£3,882 | -£4,728 | -£7,074 | -£7,743 |
| % Margin | -532.5% | -905.7% | -1,207.2% | -1,447.3% |
| EPS | -0.04 | -0.045 | -0.051 | -0.08 |
| % Growth | 10.7% | 12.7% | 36% | – |
| EPS Diluted | -0.04 | -0.045 | -0.051 | -0.079 |
| Weighted Avg Shares Out | 97,270 | 105,697 | 102,483 | 96,788 |
| Weighted Avg Shares Out Dil | 97,270 | 105,697 | 102,917 | 97,655 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £26 | £60 | £60 | £69 |
| EBITDA | -£7,502 | -£4,032 | -£5,465 | -£6,067 |
| % Margin | -1,029.1% | -772.4% | -932.6% | -1,134% |